XML 158 R101.htm IDEA: XBRL DOCUMENT v3.25.0.1
Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details) - Amunix Pharmaceuticals, Inc
€ in Millions
Feb. 08, 2022
EUR (€)
Disclosure of detailed information about business combination [line items]  
Identifiable intangible assets recognised as of acquisition date € 493
Other Current Assets And Current Liabilities As Of Acquisition Date (13)
Cash and cash equivalents recognised as of acquisition date 118
Deferred tax liabilities recognised as of acquisition date (81)
Net assets 517
Goodwill recognised as of acquisition date 609
Consideration transferred, acquisition-date fair value € 1,126